Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
André João Rossi
Observed names:
A. Rossi,
Andre Joao Rossi
Institutions:
Instituto do Câncer do Estado de São Paulo,
D’Or Institute for Research and Education
Observed institutions:
Universidade de São Paulo,
Instituto do Câncer do Estado de São Paulo,
D’Or Institute for Research and Education,
Azienda Ospedaliera Sant'Andrea,
Sapienza University of Rome
ORCID:
0009-0004-4512-9665
Observed ORCID:
0009-0004-4512-9665
OpenAlex ID:
A5040989611
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study
2025
·
Soraia Lobo-Martins
, Veronique Debien
, et al.
·
Clinical Breast Cancer
·
3
Impact of pembrolizumab infusion timing on outcomes in early-stage triple-negative breast cancer: A real-world exploratory analysis (Neo-Real).
2026
·
Natalia Nunes
, Renata Colombo Bonadio
, et al.
·
Journal of Clinical Oncology
·
1
Role of secondary cytoreduction in relapsed ovarian cancer
2024
·
Mariana Carvalho Gouveia
, Yumi Ricucci Shinkado
, et al.
·
International Journal of Gynecological Cancer
·
1
Abstracts
2011
·
V. Dunet
, A. Dabiri
, et al.
·
European Heart Journal Supplements
·
1
Time to treatment initiation for triple-negative breast cancer in Brazil: A call for public health action.
2026
·
Fernanda Madasi Pinheiro
, Renata Colombo Bonadio
, et al.
·
Journal of Clinical Oncology
1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials
2022
·
L. Marandino
, F. Trastu
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
8
Citation count:
8
H-index:
1
I10-index:
Year
Topic
Type